Previous volumes in this series have discussed the current progression have identified a variety of targets and strategies state of our knowledge concerning the pathophysiology of to allow these goals to be realized. This volume critically cancer growth and progression. The complexity of the in­ reviews approaches towards cancer management in man at teraction of malignant neoplasms and the host, the the levels of: detection, diagnosis, surgery, radiology, heterogeneity of malignant cell subpopulations, and the chronobiology and endocrine treatment. existence of metastatic tumor cells resistant to drug thera­ Several chapters review selected methods of cancer diag­ pies remain as significant clinical challenges to clinical on­ nosis. In addition, a variety of on-going and novel ap­ cologists. Indeed, conventional treatment regimens of che­ proaches for cancer treatment are also presented in this volume. Progress in the early detection of malignant neo­ motherapy, surgery and radiology are often ineffective for the therapy of a large variety of established metastatic can­ plasms, coupled with novel approaches for the therapy of cer in patients. When one considers the insidiousness of such neoplasms, may ultimately yield safe and well-tolerated agents for the selective therapy of solid malignancies. New progressive neoplastic growth and the emergence of con­ tinuously more aggressive and malignant cellular subpop­ therapeutic approaches, directed towards the biochemical ulations one is overwhelmed with the challenges inherent in and molecular targets identified in the earlier volumes of this series, may ultimately lead to the generation of new mo­ attempting to control malignant neoplasms.

Previous volumes in this series have discussed the current progression have identified a variety of targets and strategies state of our knowledge concerning the pathophysiology of to allow these goals to be realized. This volume critically cancer growth and progression. The complexity of the in­ reviews approaches towards cancer management in man at teraction of malignant neoplasms and the host, the the levels of: detection, diagnosis, surgery, radiology, heterogeneity of malignant cell subpopulations, and the chronobiology and endocrine treatment. existence of metastatic tumor cells resistant to drug thera­ Several chapters review selected methods of cancer diag­ pies remain as significant clinical challenges to clinical on­ nosis. In addition, a variety of on-going and novel ap­ cologists. Indeed, conventional treatment regimens of che­ proaches for cancer treatment are also presented in this volume. Progress in the early detection of malignant neo­ motherapy, surgery and radiology are often ineffective for the therapy of a large variety of established metastatic can­ plasms, coupled with novel approaches for the therapy of cer in patients. When one considers the insidiousness of such neoplasms, may ultimately yield safe and well-tolerated agents for the selective therapy of solid malignancies. New progressive neoplastic growth and the emergence of con­ tinuously more aggressive and malignant cellular subpop­ therapeutic approaches, directed towards the biochemical ulations one is overwhelmed with the challenges inherent in and molecular targets identified in the earlier volumes of this series, may ultimately lead to the generation of new mo­ attempting to control malignant neoplasms.

Previous volumes in this series have discussed the current progression have identified a variety of targets and strategies state of our knowledge concerning the pathophysiology of to allow these goals to be realized. This volume critically cancer growth and progression. The complexity of the in­ reviews approaches towards cancer management in man at teraction of malignant neoplasms and the host, the the levels of: detection, diagnosis, surgery, radiology, heterogeneity of malignant cell subpopulations, and the chronobiology and endocrine treatment. existence of metastatic tumor cells resistant to drug thera­ Several chapters review selected methods of cancer diag­ pies remain as significant clinical challenges to clinical on­ nosis. In addition, a variety of on-going and novel ap­ cologists. Indeed, conventional treatment regimens of che­ proaches for cancer treatment are also presented in this volume. Progress in the early detection of malignant neo­ motherapy, surgery and radiology are often ineffective for the therapy of a large variety of established metastatic can­ plasms, coupled with novel approaches for the therapy of cer in patients. When one considers the insidiousness of such neoplasms, may ultimately yield safe and well-tolerated agents for the selective therapy of solid malignancies. New progressive neoplastic growth and the emergence of con­ tinuously more aggressive and malignant cellular subpop­ therapeutic approaches, directed towards the biochemical ulations one is overwhelmed with the challenges inherent in and molecular targets identified in the earlier volumes of this series, may ultimately lead to the generation of new mo­ attempting to control malignant neoplasms.

Previous volumes in this series have discussed the current progression have identified a variety of targets and strategies state of our knowledge concerning the pathophysiology of to allow these goals to be realized. This volume critically cancer growth and progression. The complexity of the in­ reviews approaches towards cancer management in man at teraction of malignant neoplasms and the host, the the levels of: detection, diagnosis, surgery, radiology, heterogeneity of malignant cell subpopulations, and the chronobiology and endocrine treatment. existence of metastatic tumor cells resistant to drug thera­ Several chapters review selected methods of cancer diag­ pies remain as significant clinical challenges to clinical on­ nosis. In addition, a variety of on-going and novel ap­ cologists. Indeed, conventional treatment regimens of che­ proaches for cancer treatment are also presented in this volume. Progress in the early detection of malignant neo­ motherapy, surgery and radiology are often ineffective for the therapy of a large variety of established metastatic can­ plasms, coupled with novel approaches for the therapy of cer in patients. When one considers the insidiousness of such neoplasms, may ultimately yield safe and well-tolerated agents for the selective therapy of solid malignancies. New progressive neoplastic growth and the emergence of con­ tinuously more aggressive and malignant cellular subpop­ therapeutic approaches, directed towards the biochemical ulations one is overwhelmed with the challenges inherent in and molecular targets identified in the earlier volumes of this series, may ultimately lead to the generation of new mo­ attempting to control malignant neoplasms.